Company intelligence / Profile preview

Dalian Wanchun Pharmaceutical

Dalian, Liaoning, China

Ownership: Private
Development stage: Other

Overview

Plinabulin, a class-one innovative small molecule drug, has completed Phase 2 trials for NSCLC in the U.S. (by Nereus Inc.), and is progressing towards launch approval in China, with HER2-negative breast cancer also in development as an active indication

Therapeutic areas: Oncology
Modalities: Small moleculePeptide
Industry: Biotech

Partnerships

Fosun Pharma (major joint venture/incubation partnership)BeyondSpring Pharmaceuticals (originator/partner for Plinabulin, cross-border IP/resources)Jiangsu Hengrui Medicine (funding partner)

Beyond the preview

Go deeper on Dalian Wanchun Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dalian Wanchun Pharmaceutical.

Explore the full profile